2018
DOI: 10.1159/000486285
|View full text |Cite
|
Sign up to set email alerts
|

Proteomic Profiling of Diffuse Large B-Cell Lymphomas

Abstract: Objective: The aim of this study was to identify differences in proteome profiles of diffuse large B-cell lymphoma (DLBCL) of nongerminal center (non-GC) versus GC type in the search for new markers and drug targets. Methods: Six DLBCL, with 3 repeats for each, were used for the initial study by proteomics: 3 non-GC and 3 GC DLBCL cases. For immunohistochemistry, tissue microarrays were made from 31 DLBCL samples: 16 non-GC de novo lymphomas and 15 GC cases (11 transformed from follicular lymphomas and 4 de no… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
5
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 20 publications
0
5
0
Order By: Relevance
“…In a recent proteomic study [12], which also could separate ABC and GCB patients by their global protein profile in FFPE samples (n ¼ 42), we could significantly reproduce 6 of 8 proteins in their separating 8-protein signature. Three other smaller studies have also performed proteomic COO analyses in DLBCL patients [9][10][11]; however, they could not reproduce well-known COO proteins and even if there was some minor overlap, none of their top-upregulated proteins in the different subgroups were upregulated in our study. In summary, we believe that the reliability of our protein identification and expression patterns is high, judging by the overlap both of the proteins identified by the Deeb and Reinders studies and most of the corresponding genes separating the ABC subtype from GCB in the Lymph2cx gene chip, as well as a reproduction of some of the differentially regulated proteins using immunohistochemical staining.…”
Section: Discussionmentioning
confidence: 83%
See 1 more Smart Citation
“…In a recent proteomic study [12], which also could separate ABC and GCB patients by their global protein profile in FFPE samples (n ¼ 42), we could significantly reproduce 6 of 8 proteins in their separating 8-protein signature. Three other smaller studies have also performed proteomic COO analyses in DLBCL patients [9][10][11]; however, they could not reproduce well-known COO proteins and even if there was some minor overlap, none of their top-upregulated proteins in the different subgroups were upregulated in our study. In summary, we believe that the reliability of our protein identification and expression patterns is high, judging by the overlap both of the proteins identified by the Deeb and Reinders studies and most of the corresponding genes separating the ABC subtype from GCB in the Lymph2cx gene chip, as well as a reproduction of some of the differentially regulated proteins using immunohistochemical staining.…”
Section: Discussionmentioning
confidence: 83%
“…Instead, methods to directly study the global protein expression and interaction could bring new knowledge regarding the pathophysiology of DLBCL subgroups. Some global protein expression studies using a proteomic approach where non-GCB or ABC patients are compared to controls or their GCB counterpart have been published [8][9][10][11][12]. Even though these studies show promising results, the results have been diverging which at least partly could be explained by the use of different techniques and perhaps foremost the low total number of included patients (ranging from a total of 6-42 patients).…”
Section: Introductionmentioning
confidence: 99%
“…Before matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis, the gel containing separated proteins was image analyzed to determine the band intensity and sizes of the proteins using GelAnalyzer 2010a software ( Bourven et al., 2012 ) and later tryptic digested. MALDI TOF/MS analysis was performed following Kwiecińska et al. (2018) .…”
Section: Resultsmentioning
confidence: 99%
“…A proteomic study, with subsequent validation, identified GRP78 as differentially expressed in non-GC (germinal center, higher expression) as compared to GC-DLBCL (diffuse large B-cell lymphoma) [ 131 ] thus highlighting the importance of this protein in lymphoma as well as in leukemia (see previous paragraphs). GRP78, in fact, is related to worse OS of DLBCL patients as well as related to bortezomib-resistance in DLBCL cell lines [ 132 ].…”
Section: Hsp70 and Its Targeting In Onco-hematological Diseasesmentioning
confidence: 99%